Novo Nordisk A/S
2.3.2026 16:55:27 CET | Globenewswire | Press release
Election of employee representatives to the Board of Directors of Novo Nordisk A/S
Election of employee representatives to the Board of Directors of Novo Nordisk A/S
Bagsværd, Denmark, 2 March 2026 – The employees in Novo Nordisk A/S have completed the election of employee representatives to the Board of Directors of Novo Nordisk A/S.
The following employee representatives were elected for the next four years:
- Semsi Kilic Madsen (new)
- Mette Bøjer Jensen (re-elected)
- Elisabeth Dahl Christensen (re-elected)
- Désirée Jantzen Asgreen (new)
The following were elected as substitutes for the employee-elected board members:
- Trine Hartvig Kristiansen
- Tamara Schmidt
- Tanja Villumsen
- Hassan Kassem
The newly elected employee representatives will join the Board of Directors following the annual general meeting of Novo Nordisk A/S on 26 March 2026. At the same time, the current board members Liselotte Hyveled and Tanja Villumsen, who did not run for election as employee representatives, will resign.
About employee-elected board members
According to the Danish Companies Act, the employees of Novo Nordisk A/S are entitled to be represented by half of the total shareholder-elected Board members. Employee-elected board members serve for a statutory four-year term and have the same rights, duties and responsibilities as shareholder-elected board members.
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Contacts for further information
| Novo Nordisk Media: | |
| Ambre James-Brown +45 3079 9289 globalmedia@novonordisk.com | Liz Skrbkova (US) +1 609 917 0632 lzsk@novonordisk.com |
| Novo Nordisk Investors: | |
| Michael Novod +45 3075 6050 nvno@novonordisk.com | Jacob Martin Wiborg Rode +45 3075 5956 jrde@novonordisk.com |
| Sina Meyer +45 3079 6656 azey@novonordisk.com | Max Ung +45 3077 6414 mxun@novonordisk.com |
| Christoffer Sho Togo Tullin +45 3079 1471 cftu@novonordisk.com | Alex Bruce +45 3444 2613 axeu@novonordisk.com |
| Frederik Taylor Pitter +1 609 613 0568 fptr@novonordisk.com |
Company Announcement No 16 / 2026
Attachment
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Beam Global15.10.2026 12:00:00 CEST | Press release
Beam Global's Pending Drone Company Acquisition ScoutDI Wins Milestone Order from Nuclear Sector Customer
Zymeworks Inc.15.10.2026 12:00:00 CEST | Press release
Zymeworks Announces Participation in Upcoming Investor Conferences and Date of Third Quarter 2026 Financial Results
Affidea Group15.10.2026 12:00:00 CEST | Press release
Affidea signs agreement to acquire two Alliance Medical centres in central London, accelerating its UK growth
Kalmar Corporation15.10.2026 12:00:00 CEST | Press release
Kalmar’s Interim Report for January–September 2026 to be published on Thursday, 29 October 2026
Harvia Oyj15.10.2026 12:00:00 CEST | Press release
Harvia Plc distributes a dividend of EUR 0.38 per share
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom